REFERENCES
1. Stark BA, Decleene NK, Desai EC, et al. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. J Am Coll Cardiol. 2025;86:2167-243.
2. Goh LH, Chong B, Van Der Lubbe SC, et al. The epidemiology and burden of cardiovascular diseases in countries of the Association of Southeast Asian Nations (ASEAN), 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10:e467-79.
3. Zendjebil S, Steg PG. PCSK9 monoclonal antibodies have come a long way. Curr Atheroscler Rep. 2024;26:721-32.
4. Wang R, Maron BA, Loscalzo J. Multiomics network medicine approaches to precision medicine and therapeutics in cardiovascular diseases. Arterioscler Thromb Vasc Biol. 2023;43:493-503.
5. Arduini A, Fleming SJ, Xiao L, et al. Transcriptional profile of the rat cardiovascular system at single-cell resolution. Cell Rep. 2025;44:115091.
6. Santovito D, Weber C. Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease. Nat Rev Cardiol. 2022;19:620-38.
7. Lee S. Cardiovascular disease and miRNAs: possible oxidative stress-regulating roles of miRNAs. Antioxidants. 2024;13:656.
8. Xie X, Huang M, Ma S, et al. The role of long non-coding RNAs in cardiovascular diseases: a comprehensive review. Non-Coding RNA Res. 2025;11:158-87.
9. Borchardt EK, Martinez NM, Gilbert WV. Regulation and function of RNA pseudouridylation in human cells. Annu Rev Genet. 2020;54:309-36.
10. Duan C, Abola Y, Zhao J, Wang Y. Small nucleolar RNAs in head and neck squamous cell carcinomas. J Dent Res. 2024;104:5-16.
11. Migeot V, Mary Y, Fafard-Couture E, et al. RNase III cleavage sites spread across splice junctions enforce sequential snoRNA processing. EMBO Rep. 2025;26:4675-90.
12. Kiss-László Z, Henry Y, Bachellerie J, Caizergues-Ferrer M, Kiss T. Site-specific ribose methylation of preribosomal RNA: a novel function for small nucleolar RNAs. Cell. 1996;85:1077-88.
13. Cavaillé J, Nicoloso M, Bachellerie J. Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides. Nature. 1996;383:732-5.
14. Wang Y, Fu M, Zheng Z, Feng J, Zhang C. Small nucleolar RNAs: biological functions and diseases. MedComm. 2025;6:e70257.
15. Lin Z, Chang J, Li X, et al. Association of DNA methylation and transcriptome reveals epigenetic etiology of heart failure. Funct Integr Genomics. 2021;22:89-112.
16. Nossent AY, Ektefaie N, Wojta J, et al. Plasma levels of snoRNAs are associated with platelet activation in patients with peripheral artery disease. Int J Mol Sci. 2019;20:5975.
17. Håkansson KEJ, Goossens EAC, Trompet S, et al. Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovasc Res. 2019;115:1519-32.
18. Boivin V, Faucher-Giguère L, Scott M, Abou-Elela S. The cellular landscape of mid-size noncoding RNA. WIREs RNA. 2019;10:e1530.
20. Huo M, Rai SK, Nakatsu K, Deng Y, Jijiwa M. Subverting the canon: novel cancer-promoting functions and mechanisms for snoRNAs. Int J Mol Sci. 2024;25:2923.
21. Deryusheva S, Gall JG. Small, smaller, smallest: minimal structural requirements for a fully functional box C/D modification guide RNA. Biomolecules. 2019;9:457.
22. Deschamps-Francoeur G, Couture S, Abou-Elela S, Scott MS. The snoGloBe interaction predictor reveals a broad spectrum of C/D snoRNA RNA targets. Nucleic Acids Res. 2022;50:6067-83.
23. Trucks S, Hanspach G, Hengesbach M. Eukaryote specific RNA and protein features facilitate assembly and catalysis of H/ACA snoRNPs. Nucleic Acids Res. 2021;49:4629-42.
24. Caton EA, Kelly EK, Kamalampeta R, Kothe U. Efficient RNA pseudouridylation by eukaryotic H/ACA ribonucleoproteins requires high affinity binding and correct positioning of guide RNA. Nucleic Acids Res. 2018;46:905-16.
25. De Zoysa MD, Wu G, Katz R, Yu Y. Guide-substrate base-pairing requirement for box H/ACA RNA-guided RNA pseudouridylation. RNA. 2018;24:1106-17.
26. Izumikawa K, Nobe Y, Ishikawa H, et al. TDP-43 regulates site-specific 2′-O-methylation of U1 and U2 snRNAs via controlling the Cajal body localization of a subset of C/D scaRNAs. Nucleic Acids Res. 2019;47:2487-505.
27. Jorjani H, Kehr S, Jedlinski DJ, et al. An updated human snoRNAome. Nucleic Acids Res. 2016;44:5068-82.
28. Kishore S, Gruber AR, Jedlinski DJ, Syed AP, Jorjani H, Zavolan M. Insights into snoRNA biogenesis and processing from PAR-CLIP of snoRNA core proteins and small RNA sequencing. Genome Biol. 2013;14:R45.
30. Zhang X, Yin Q, Wang H, et al. Species-specific alternative splicing leads to unique expression of sno-lncRNAs. BMC Genomics. 2014;15:287.
31. Kocher MA, Huang FW, Le E, Good DJ. Snord116 post-transcriptionally increases Nhlh2 mRNA Stability: implications for human Prader-Willi syndrome. Hum Mol Genet. 2021;30:1101-10.
32. Elliott BA, Ho H, Ranganathan SV, et al. Modification of messenger RNA by 2′-O-methylation regulates gene expression in vivo. Nat Commun. 2019;10:3401.
33. Zhang D, Li B, Xu H, et al. Identification of FBLL1 as a neuron-specific RNA 2′-O-methyltransferase mediating neuronal differentiation. Proc Natl Acad Sci USA. 2024;121:e2406961121.
34. Li Y, Yi Y, Gao X, et al. 2′-O-methylation at internal sites on mRNA promotes mRNA stability. Mol Cell. 2024;84:2320-36.e6.
35. Vitali P, Kiss T. Cooperative 2′-O-methylation of the wobble cytidine of human elongator tRNAMet (CAT) by a nucleolar and a Cajal body-specific box C/D RNP. Genes Dev. 2019;33:741-6.
36. Zhang M, Li K, Bai J, et al. A snoRNA-tRNA modification network governs codon-biased cellular states. Proc Natl Acad Sci USA. 2023;120:e2312126120.
37. Nir R, Hoernes TP, Muramatsu H, et al. A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA. Nucleic Acids Res. 2022;50:4900-16.
38. Pan Y, Kierzek E, Kierzek R, Mathews DH, Yu Y. A Ψ-Ψ codon-anticodon pairing in nonsense suppression and translational recoding. Nat Chem Biol. 2026;22:983-94.
39. King TH, Liu B, Mccully RR, Fournier MJ. Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol Cell. 2003;11:425-35.
40. Sabe SA, Feng J, Sellke FW, Abid MR. Mechanisms and clinical implications of endothelium-dependent vasomotor dysfunction in coronary microvasculature. Am J Physiol Heart Circ Physiol. 2022;322:H819-41.
41. Yan Q, Zhou J, Wang Z, et al. NAT10-dependent N4-acetylcytidine modification mediates PAN RNA stability, KSHV reactivation, and IFI16-related inflammasome activation. Nat Commun. 2023;14:6327.
42. Yu J, Jin J, Kwon E, et al. Programmable RNA acetylation with CRISPR-Cas13. Nat Chem Biol. 2026;22:969-82.
43. Sas-Chen A, Thomas JM, Matzov D, et al. Dynamic RNA acetylation revealed by quantitative cross-evolutionary mapping. Nature. 2020;583:638-43.
44. Sharma S, Langhendries J, Watzinger P, Kötter P, Entian K, Lafontaine DL. Yeast Kre33 and human NAT10 are conserved 18S rRNA cytosine acetyltransferases that modify tRNAs assisted by the adaptor Tan1/THUMPD1. Nucleic Acids Res. 2015;43:2242-58.
45. Sharma S, Yang J, Van Nues R, et al. Specialized box C/D snoRNPs act as antisense guides to target RNA base acetylation. PLoS Genet. 2017;13:e1006804.
46. Dudnakova T, Dunn-Davies H, Peters R, Tollervey D. Mapping targets for small nucleolar RNAs in yeast. Wellcome Open Res. 2018;3:120.
47. Lu Z, Zhang QC, Lee B, et al. RNA duplex map in living cells reveals higher-order transcriptome structure. Cell. 2016;165:1267-79.
48. Bortolin-Cavaillé M, Quillien A, Thalalla Gamage S, et al. Probing small ribosomal subunit RNA helix 45 acetylation across eukaryotic evolution. Nucleic Acids Res. 2022;50:6284-99.
49. Thalalla Gamage S, Howpay Manage SA, Chu TT, Meier JL. Cytidine acetylation across the tree of life. Acc Chem Res. 2024;57:338-48.
50. Liu Y, Demario S, He K, Gibbs MR, Barr KW, Chanfreau GF. Splicing inactivation generates hybrid mRNA-snoRNA transcripts targeted by cytoplasmic RNA decay. Proc Natl Acad Sci USA. 2022;119:e2202473119.
51. Cihlarova Z, Kubovciak J, Sobol M, et al. BRAT1 links Integrator and defective RNA processing with neurodegeneration. Nat Commun. 2022;13:5026.
52. Huang C, Shi J, Guo Y, et al. A snoRNA modulates mRNA 3′ end processing and regulates the expression of a subset of mRNAs. Nucleic Acids Res. 2017;45:8647-60.
53. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463:457-63.
54. Bergeron D, Faucher-Giguère L, Emmerichs A, et al. Intronic small nucleolar RNAs regulate host gene splicing through base pairing with their adjacent intronic sequences. Genome Biol. 2023;24:160.
55. Song Z, Bae B, Schnabl S, et al. Mapping snoRNA-target RNA interactions in an RNA-binding protein-dependent manner with chimeric eCLIP. Genome Biol. 2025;26:39.
56. Liu B, Wu T, Miao BA, et al. snoRNA-facilitated protein secretion revealed by transcriptome-wide snoRNA target identification. Cell. 2025;188:465-83.e22.
57. Taft RJ, Glazov EA, Lassmann T, Hayashizaki Y, Carninci P, Mattick JS. Small RNAs derived from snoRNAs. RNA. 2009;15:1233-40.
58. Langenberger D, Çakir MV, Hoffmann S, Stadler PF. Dicer-processed small RNAs: rules and exceptions. J Exp Zool Pt B. 2012;320:35-46.
59. Lemus-Diaz N, Ferreira RR, Bohnsack KE, Gruber J, Bohnsack MT. The human box C/D snoRNA U3 is a miRNA source and miR-U3 regulates expression of sortin nexin 27. Nucleic Acids Res. 2020;48:8074-89.
60. Kishore S, Khanna A, Zhang Z, et al. The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet. 2010;19:1153-64.
61. Calandrelli R, Wen X, Charles Richard JL, et al. Genome-wide analysis of the interplay between chromatin-associated RNA and 3D genome organization in human cells. Nat Commun. 2023;14:6519.
62. Schubert T, Pusch MC, Diermeier S, et al. Df31 protein and snoRNAs maintain accessible higher-order structures of chromatin. Mol Cell. 2012;48:434-44.
63. Lin X, Leung KSK, Wolfe KF, et al. XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites. Nucleic Acids Res. 2025;53:gkaf086.
64. Kim D, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL. Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21. Mol Cell. 2019;75:1270-85.e14.
65. Han C, Sun L, Luo X, et al. Chromatin-associated orphan snoRNA regulates DNA damage-mediated differentiation via a non-canonical complex. Cell Rep. 2022;38:110421.
66. Shi J, Yang C, Zhang J, et al. NAT10 is involved in cardiac remodeling through ac4C-mediated transcriptomic regulation. Circ Res. 2023;133:989-1002.
67. Li P, Qin D, Chen T, et al. Dysregulated Rbfox2 produces aberrant splicing of CaV1.2 calcium channel in diabetes-induced cardiac hypertrophy. Cardiovasc Diabetol. 2023;22:168.
68. Vad OB, Angeli E, Liss M, et al. Loss of cardiac splicing regulator RBM20 is associated with early-onset atrial fibrillation. JACC Basic Transl Sci. 2024;9:163-80.
69. Deng Z, Li C, Hu S, et al. sdRNA-D43 derived from small nucleolar RNA snoRD43 improves chondrocyte senescence and osteoarthritis progression by negatively regulating PINK1/Parkin-mediated mitophagy pathway via dual-targeting NRF1 and WIPI2. Cell Commun Signal. 2025;23:77.
70. Meng X, Song M, Zhang K, et al. Congenital heart disease: types, pathophysiology, diagnosis, and treatment options. MedComm. 2024;5:e631.
71. Rao E, Annavarapu S. Genetics of congenital heart disease: a narrative review of challenges and strategies in identifying novel genes. Cureus. 2025;17:e91674.
72. Wang H, Chen X, Li Y, et al. Non-coding RNAs in congenital heart disease and placental development: Bridging molecular mechanisms to clinical biomarkers and therapies. Non-coding RNA Res. 2026;16:1-20.
73. Patil P, Kibiryeva N, Uechi T, et al. scaRNAs regulate splicing and vertebrate heart development. Biochim Biophys Acta Mol Basis Dis. 2015;1852:1619-29.
74. O'brien JE, Kibiryeva N, Zhou X, et al. Noncoding RNA expression in myocardium from infants with tetralogy of fallot. Circ Cardiovasc Genet. 2012;5:279-86.
75. Ogren A, Kibiryeva N, Marshall J, O’brien JE, Bittel DC. Snord94 expression level alters methylation at C62 in snRNA U6. PLoS ONE. 2019;14:e0226035.
76. Brown M, Earl B, Filla M, Kibiryeva N, O’brien JE, Bittel DC. scaRNA1 expression levels affect alternative splicing of mRNA. Genes. 2025;16:864.
77. Nagasawa CK, Kibiryeva N, Marshall J, O’brien JE, Bittel DC. scaRNA1 levels alter pseudouridylation in spliceosomal RNA U2 affecting alternative mRNA splicing and embryonic development. Pediatr Cardiol. 2020;41:341-9.
78. Lei W, Wen C, Li H, et al. An interpretable deep learning model for first-trimester fetal cardiac screening. NPJ Digit Med. 2025;9:43.
79. Huang S, Li J, Li Q, et al. Cardiomyopathy: pathogenesis and therapeutic interventions. MedComm. 2024;5:e772.
80. Shimoda M, Morita S, Obata Y, Sotomaru Y, Kono T, Hatada I. Imprinting of a small nucleolar RNA gene on mouse chromosome 12. Genomics. 2002;79:483-6.
81. Siira SJ, Rossetti G, Richman TR, et al. Concerted regulation of mitochondrial and nuclear non-coding RNAs by a dual-targeted RNase Z. EMBO Rep. 2018;19:EMBR201846198.
82. Tallo CA, Duncan LH, Yamamoto AH, et al. Heat shock proteins and small nucleolar RNAs are dysregulated in a Drosophila model for feline hypertrophic cardiomyopathy. G3. 2021;11:jkaa014.
83. James V, Nizamudeen ZA, Lea D, et al. Transcriptomic analysis of cardiomyocyte extracellular vesicles in hypertrophic cardiomyopathy reveals differential snoRNA cargo. Stem Cells Dev. 2021;30:1215-27.
84. Epstein FH, Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-8.
85. Wang S, Yang L, Zhao A, et al. A novel hidden protein p-414aa encoded by circSETD2(14,15) inhibits vascular remodeling. Circulation. 2025;151:1568-82.
86. Liu P, Hu L, Shi Y, et al. Changes in the small RNA expression in endothelial cells in response to inflammatory stimulation. Oxid Med Cell Longev. 2021;2021:8845520.
87. Yang X, Li M, Wang H, et al. SNORD45A affects content of HIF-1α and promotes endothelial angiogenic function. Appl Biochem Biotechnol. 2024;196:7185-97.
88. Van Ingen E, Van Den Homberg DAL, Van Der Bent ML, et al. C/D box snoRNA SNORD113-6/AF357425 plays a dual role in integrin signalling and arterial fibroblast function via pre-mRNA processing and 2′O-ribose methylation. Hum Mol Genet. 2022;31:1051-66.
89. Van Ingen E, Engbers PA, Woudenberg T, et al. C/D box snoRNA SNORD113-6 guides 2′-O-methylation and protects against site-specific fragmentation of tRNALeu(TAA) in vascular remodeling. Mol Ther Nucleic Acids. 2022;30:162-72.
90. Rahimi AM, Cai M, Hoyer-Fender S. Heterogeneity of the NIH3T3 fibroblast cell line. Cells. 2022;11:2677.
91. Youness M, Ekhteraei-Tousi S, Nagaraju CK, et al. Location and aetiology are determinants of fibroblast activation and heterogeneity in the failing human heart. Genome Med. 2025;17:155.
92. Amrute JM, Luo X, Penna V, et al. Targeting immune-fibroblast cell communication in heart failure. Nature. 2024;635:423-33.
93. Chauhan W, Sj S, Ferdowsi S, Sohel A, Zennadi R. Red blood cell Rpl13a small noncoding nucleolar RNAs guides 2'-O-methylation on peroxidasin messenger RNA promoting venous thrombosis in aging. J Thromb Haemost. 2025:S1538783625001357.
94. Chauhan W, Ferdowsi S, Sudharshan S, Zennadi R. Rpl13a snoRNAs-regulated NADPH oxidase 1-dependent ROS generation: a novel RBC pathway mediating complement C3a deposition and triggering thrombosis in aging and venous blood clotting disorders. Free Radic Biol Med. 2025;230:138-50.
95. Engelen SE, Robinson AJB, Zurke Y, Monaco C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. 2022;19:522-42.
96. Yao Z, Tasdighi E, Dardari ZA, et al. Association between cigarette smoking and subclinical markers of cardiovascular harm. J Am Coll Cardiol. 2025;85:1018-34.
97. Keshawarz A, Joehanes R, Guan W, et al. Longitudinal change in blood DNA epigenetic signature after smoking cessation. Epigenetics. 2021;17:1098-109.
98. Aboyans V, Canonico ME, Chastaingt L, et al. Peripheral artery disease. Nat Rev Dis Primers. 2025;11:68.
99. Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat Rev Cardiol. 2022;19:456-74.
100. Håkansson KEJ, Sollie O, Simons KH, Quax PHA, Jensen J, Nossent AY. Circulating small non-coding RNAs as biomarkers for recovery after exhaustive or repetitive exercise. Front Physiol. 2018;9:1136.
101. Jain K, Tyagi T, Gu SX, Faustino EVS, Hwa J. Demographic diversity in platelet function and response to antiplatelet therapy. Trends Pharmacol Sci. 2025;46:78-93.
102. Sayer M, Webb DJ, Dhaun N. Novel pharmacological approaches to lowering blood pressure and managing hypertension. Nat Rev Cardiol. 2025;22:649-63.
103. Delgado-Olguín P, Huang Y, Li X, et al. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet. 2012;44:343-7.
104. He A, Ma Q, Cao J, et al. Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res. 2012;110:406-15.
105. Wang S, Guo N, Li S, et al. EZH2 dynamically associates with non-coding RNAs in mouse hearts after acute angiotensin II treatment. Front Cardiovasc Med. 2021;8:585691.
106. Witte F, Ruiz-Orera J, Mattioli CC, et al. A trans locus causes a ribosomopathy in hypertrophic hearts that affects mRNA translation in a protein length-dependent fashion. Genome Biol. 2021;22:191.
107. Wang J, Kuang J, Zhang S, et al. Comprehensive characterization of small noncoding RNA profiles in hypoxia-induced pulmonary hypertension (HPH) rat tissues. iScience. 2024;27:108815.
108. Heusch G, Kleinbongard P. The spleen in ischaemic heart disease. Nat Rev Cardiol. 2025;22:497-509.
109. Mamaev NN, Kovalyeva OV, Amineva K, et al. AgNORs in cardiomyocytes from surgical patients with coronary heart disease. Mol Pathol. 1998;51:218-21.
110. Freedman JE, Gerstein M, Mick E, et al. Corrigendum: Diverse human extracellular RNAs are widely detected in human plasma. Nat Commun. 2016;7:11902.
111. Mick E, Shah R, Tanriverdi K, et al. Stroke and circulating extracellular RNAs. Stroke. 2017;48:828-34.
112. Chapman AR, Taggart C, Boeddinghaus J, Mills NL, Fox KAA. Type 2 myocardial infarction: challenges in diagnosis and treatment. Eur Heart J. 2025;46:504-17.
113. Pan W, An Y, Guan Y, Wang J. MCA-net: a multi-task channel attention network for Myocardial infarction detection and location using 12-lead ECGs. Comput Biol Med. 2022;150:106199.
114. Shumliakivska M, Fischer A, Muhly-Reinholz M, et al. The long non-coding RNA Snhg15 protects the heart after myocardial infarction. J Mol Cell Cardiol. 2026;210:72-82.
115. Wang S, Cheng Z, Chen X, Lu G, Zhu X, Xu G. Long noncoding RNA SNHG4 attenuates the injury of myocardial infarction via regulating miR-148b-3p/DUSP1 axis. Cardiovasc Ther. 2022;2022:1-15.
116. Hobby ARH, Berretta RM, Eaton DM, et al. Cortical bone stem cells modify cardiac inflammation after myocardial infarction by inducing a novel macrophage phenotype. Am J Physiol Heart Circ Physiol. 2021;321:H684-701.
117. Yang Y, Johnson J, Troupes CD, et al. miR-182/183-Rasa1 axis induced macrophage polarization and redox regulation promotes repair after ischemic cardiac injury. Redox Biol. 2023;67:102909.
118. Schena GJ, Murray EK, Hildebrand AN, et al. Cortical bone stem cell-derived exosomes’ therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling. Am J Physiol Heart Circ Physiol. 2021;321:H1014-29.
119. Zeng Y, Yuan Z, Li J, et al. Small non-coding RNA signatures in atrial appendages of patients with atrial fibrillation. J Cell Mol Med. 2024;28:e18483.
120. Bauersachs J, De Boer RA, Lindenfeld J, Bozkurt B. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J. 2022;43:367-76.
121. Li X, Zhao X, Xie L, Song X, Song X. Identification of four snoRNAs (SNORD16, SNORA73B, SCARNA4, and SNORD49B) as novel non-invasive biomarkers for diagnosis of breast cancer. Cancer Cell Int. 2024;24:55.
122. Grützmann K, Salomo K, Krüger A, et al. Identification of novel snoRNA-based biomarkers for clear cell renal cell carcinoma from urine-derived extracellular vesicles. Biol Direct. 2024;19:38.
123. Rambaldelli G, Asghar S, Venturi G, et al. Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells. Non-Coding RNA Res. 2025;13:153-61.
124. Chabronova A, Holmes TL, Hoang DM, et al. SnoRNAs in cardiovascular development, function, and disease. Trends Mol Med. 2024;30:562-78.
125. Yuan S, Wu Y, Wang Y, Chen J, Chu L. An oncolytic adenovirus expressing SNORD44 and GAS5 exhibits antitumor effect in colorectal cancer cells. Hum Gene Ther. 2017;28:690-700.
126. Wang W, Sayedahmed EE, Mittal SK. Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy. Viruses. 2022;14:2727.
127. Wang X, Zhong X, Li J, Liu Z, Cheng L. Inorganic nanomaterials with rapid clearance for biomedical applications. Chem Soc Rev. 2021;50:8669-742.
128. Xuan J, Chen L, Chen Z, et al. RMBase v3.0: decode the landscape, mechanisms and functions of RNA modifications. Nucleic Acids Res. 2024;52:D273-84.
129. Zhang L, Chen M, Hu X, Deng L. Graph convolutional network and contrastive learning small nucleolar RNA (snoRNA) disease associations (GCLSDA): predicting snoRNA-disease associations via graph convolutional network and contrastive learning. Int J Mol Sci. 2023;24:14429.
